Aytu BioPharma Inc

EXXUA, Aytu BioPharma’s first 5‑HT1A agonist for major depression, is now FDA‑approved and available nationwide—offering effective treatment without sexual dysfunction or weight gain.

Aytu BioPharma, a specialty healthcare company, is making significant strides in the pharmaceutical industry by targeting critical areas such as sexual dysfunction disorders and urological conditions, with a focus on innovation and patient care.

Aytu BioPharma, Inc. is a healthcare company that stands out for its innovation and dedication to addressing unmet medical needs, particularly in areas such as sexual dysfunction disorders and urological cancers.

Aytu BioPharma reported strong Q3 2025 financials, with $18.5 million in revenue and $4.0 million in net income, exceeding expectations and marking a 32% year-over-year revenue growth.

Aytu BioPharma Inc. reported a 32% increase in net revenue and a significant turnaround in net income for its Q3 2025, driven by strong performances across its product portfolios.